BiVictriX, a UK-based emerging biotech company involved in developing next-generation cancer therapies, has raised £ 7.5 million of gross revenue after floating on the London Stock Exchange, giving a market capitalization of £ 13.2 million.
Eyes to accelerate growth
BiVictriX was advised by Manchester-based full-service law firm Slater Heelis on its admission to the AIM market. The funds will enable BiVictriX to accelerate its growth strategy and accelerate the development and delivery of its highly selective next-generation cancer therapy.
Based in Alderley Park, BiVictriX applies contemporary techniques using insights derived from first-line clinical experience to develop safer and more effective cancer therapies.
Founded by Tiffany Thorn in 2017, BiVictriX has developed a proprietary platform and the resulting Bi-Cygni therapeutics is uniquely selective for specific cancers, potentially allowing higher dosing and more aggressive tumor eradication, while reducing the life-threatening treatment-related side effects.
Rhian Owen, a partner at Slater Heelis who led the transaction team, said: “BiVictriX is an exciting company developing novel treatments. We have been delighted to help BiVictriX through its funding rounds over the years, guiding the company through its initial phases of growth until its admission to the AIM market. ”
Simon Wallwork, corporate head of the firm, said: “The Slater Heelis corporate department has vast experience in helping dynamic and early-stage biotech companies through all stages of their development, and I am proud that we have We have been able to leverage our experience and deep industry knowledge to support BiVictriX in reaching this important milestone and attracting funding to take its technology through the next stages of development. ”
Tiffany Thorn, CEO and Founder of BiVictriX Therapeutics plc, said: “The listing on the London AIM market is a major milestone for BiVictriX. Our vision is to revolutionize cancer therapy for the most difficult-to-treat cancers, making them curative treatments are available to all. Funds raised will help us accelerate our growth and accelerate the development and delivery of our pioneering and highly selective cancer therapeutics to patients diagnosed with some of the most challenging cancers and to support patients who currently they urgently need more effective drugs. “
